Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Jul 1;4(3):299-312.
doi: 10.1016/j.cpet.2009.09.001.

Disease Restaging and Diagnosis of Recurrent and Metastatic Disease Following Primary Therapy with FDG-PET Imaging

William B Eubank, Jean H Lee, David A Mankoff

Disease Restaging and Diagnosis of Recurrent and Metastatic Disease Following Primary Therapy with FDG-PET Imaging

William B Eubank et al. PET Clin. .
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Recurrence in the contralateral breast in a patient with history of left breast cancer and left partial mastectomy 10 years ago. She also underwent left total mastectomy and prophylactic right mastectomy when she had recurrence 6 years ago. Ultrasound images (a and b) show multiple hypoechoic and heterogeneous mixed echogenic lesions with shadowing in the right breast. Axial CT (c) and FDG PET-CT images (d) reveal hypermetabolic soft tissue mass and nodules with irregular skin thickening in the right breast.
Figure 2
Figure 2
Locoregional recurrence in the left posterior chest wall in a patient who had undergone left radical mastectomy 13 years ago. She had left anterolateral chest wall recurrence 5 years ago, which had been resected. CT (a), FDG PET-CT (b) and MR (c and d) images show hypermetabolic irregular mass in the left posterior chest wall extending to the epidural space of T5.
Figure 3
Figure 3
Patient with history of breast cancer. Coronal PET (a) and PET-CT images (b) show extensive bilateral axillary, mediastinal, supraclavicular and retroperitoneal nodal involvement.
Figure 4
Figure 4
Pulmonary metastasis in a patient with history of recurrent right breast cancer and widespread metastases to brain and bones. CT image (a) shows spiculated nodule in the right lower lobe (arrow). FDG PET-CT image (b) reveals hypermetabolic activity in the nodule.
Figure 5
Figure 5
Recurrence after resection of prior liver metastasis in a patient with history of breast cancer. Axial image of liver MRI following gadolinium enhancement (a) demonstrate multiple enhancing masses (arrows) that correspond to the hypermetabolic activity involving entire liver on coronal FDG PET image (b).
See this image and copyright information in PMC

References

    1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58(2):71–96. - PubMed
    1. Bender H, Kirst J, Palmedo H, et al. Value of [F-18]-fluoro-deoxyglucose positron emission tomography in the staging of recurrent breast carcinoma. Anticancer Res. 1997;17(3B):1687–92. - PubMed
    1. Moon DH, Maddahi J, Silverman DH, et al. Accuracy of whole-body [fluorine-18]-FDG PET for the detection of recurrent or metastatic breast carcinoma. J Nucl Med. 1998;39(3):431–5. - PubMed
    1. Lonneux M, Borbath II, Berliere M, et al. The Place of Whole-Body PET FDG for the Diagnosis of Distant Recurrence of Breast Cancer. Clin Positron Imaging. 2000;3(2):45–9. - PubMed
    1. Kim TS, Moon WK, Lee DS, et al. Fluorodeoxyglucose positron emission tomography for detection of recurrent or metastatic breast cancer. World J Surg. 2001;25(7):829–34. - PubMed

LinkOut - more resources